Showing 131-140 of 4262 results for "".
A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fCOVID-19 Impact: Virtual Care for Young Patients
https://practicaldermatology.com/topics/practice-management/covid-19-impact-virtual-care-for-young-patients/19765/With most dermatology practices closing their doors during the COVID-19 pandemic, telemedicine is emerging as an effective option for patient care. Peter Lio, MD offers tips for overcoming technology difficulties and enhancing communication during teleconsults. He also offers insights into how he isTalking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Guselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Using GEP Test Results to Manage Patients
https://reachmd.com/programs/practical-dermatology-updates-in-skin-cancer/using-gep-test-results-to-manage-patients/35603/Jason M. Rizzo, MD, describes how gene expression profile (GEP) testing works and how the results can be used to manage patients from a dermatologist's perspective.Patient Experience with PDT
https://practicaldermatology.com/series/pdt-in-practice/patient-experience-pdt/28863/Dr. Joel L. Cohen discusses how he implemented photodynamic therapy and describes the patient experience with it, including scheduling considerations.Increasing Patient Compliance with the Right Vehicles
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/increasing-patient-compliance-with-the-right-vehicles/18877/Peter Lio, MD and Elaine Siegfried, MD talk about their vehicles of choice to enhance patient adherence to treatment, especially when treating scalp psoriasis. They also discuss how packaging innovations have led to vehicle innovations.Educating Patients On OTC Products
https://practicaldermatology.com/topics/practice-management/educating-patients-on-otc-products/19023/Kristina Goldenberg, MD describes how to incorporate patient education into care, particularly the importance of addressing patient misconceptions regarding OTC products.